

DT14 Rec'd PCT/PTO 11 4 OCT 2004

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**10/501962**

**In re United States Patent Application of:**

**Applicant(s): Braun, et al**

**Application No.: 10/501,962**

**(National Stage Application of  
International Application No.  
PCT/DE03/00124)**

**Int'l Filing Date: 17 January 2003**

**Priority Date: 18 January 2002(German Patent  
Application No. 102 01 862.6)**

**Title: CONJUGATE FOR TREATING  
PROKARYOTIC INFECTIONS**

**Docket No.: 4121-170**

**Examiner: Not Yet Assigned**


**Art Unit: Not Yet Assigned**

**Customer No.:**

**23448**

**FIRST CLASS MAIL CERTIFICATE**

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, and First Class Mailed under the provisions of 37 CFR 1.8.

  
Joanna Joslyn

October 12, 2004  
Date of Mailing

**INFORMATION DISCLOSURE STATEMENT**


Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ c. Attached is our check no. \_\_\_\_\_ in the amount of \$\_\_\_\_\_ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. \_\_\_\_\_ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check no. \_\_\_\_\_ in the amount of \$180.00 in payment of the petition fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. \_\_\_\_\_ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,



Marianne Fuierer  
Reg. No. 39,983  
Attorney for Applicant



## Sheet 1 of 2

COMPLETE IF KNOWN

Application Number	10/501,962
Submission Date	July 19, 2004
First Named Inventor	Braun, et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4121-170

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner signature		Date Considered	
-----------------------	--	--------------------	--

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>1</sup> All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 2 of 2

*COMPLETE IF KNOWN*

Application Number	10/501,962
Filing Date	July 19, 2004
First Named Inventor	Braun, et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4121-170

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AH	Good, et al., "Bactericidal antisense effects of peptide-PNA conjugates," Nature Biotechnology, volume 19, April 2001, 360-364.	
	AI	Nielsen, Peter "Peptide nucleic acids as therapeutic agents," <a href="http://biomednet.com/elecref/095944OX00900353">http://biomednet.com/elecref/095944OX00900353</a> .	
	AJ	Braun, et al., "A biological transporter for the delivery of Peptide Nucleic Acids (PNAs) to the Nuclear Compartment of Living Cells; <a href="http://www.idealibrary.com">www.idealibrary.com</a> .	
	AK	Good, et al., "Bacterial antisense effects of peptide-PNA conjugates," Nature Biotechnology, volume 19, number 4, pp 360-364 (April 2001).	
	AL	Good, et al., "Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA," Nature Biotechnology, April 16, 1998, pp 355-358.	
	AM	Tang, et al., "A cyclic Antimicrobial Peptide Produced in Primate Leukocytes by the Ligation of Two Truncated Defensins," Science, Volume 286, October 15, 1999	
	AN	Hisako, et al., "Synthesis and characterization of bacterial oligopeptides designed on the basis of an insect anti-bacterial peptide," Biochemical Journal, 338, 29-33 (1999).	
	AO	Periathamby, et al., "Large-scale synthesis and functional elements for the antimicrobial activity of defensins," Biochemical Journal, 347, 633-641 (2000).	
	AP	Yu, et al., "Engineered Salt-insensitive Defensins with end-to-end circularized structures," The Journal of Biological Chemistry, (2000).	
	AQ	Pipkorn, et al., "Peptide Carrier for Efficient Drug Transport into Living Cells," American Peptide Society, 931-932 (2001)	
Examiner signature			Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).